Anindita Chakraborty
Overview
Explore the profile of Anindita Chakraborty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chakraborty A, Jyoti , Maji T
Dalton Trans
. 2024 Dec;
54(2):433-457.
PMID: 39618288
Metal-organic frameworks (MOFs) have become increasingly important as a class of porous crystalline materials because of their diverse applications. At the same time, significant progress has been achieved in the...
2.
Hasan M, Bag S, Halder D, Bhowmik S, Chakraborty A, Ghosh A
Sci Rep
. 2024 Aug;
14(1):19707.
PMID: 39181952
Synthetic textile dye malachite green (MG) and heavy metals present in industrial wastewater are hazardous to the ecosystem. Bioremediation of dyes and heavy metals using dry-biomasses has advantages over chemical...
3.
Marni R, Malla M, Chakraborty A, Voonna M, Bhattacharyya P, Kgk D, et al.
Cancer Chemother Pharmacol
. 2024 Aug;
94(5):685-706.
PMID: 39167147
Background: Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer and is frequently resistant to therapy, ultimately resulting in treatment failure. Clinical trials have demonstrated the potential...
4.
Chakraborty A, Nandi R, Kumar D, Acharya H
ACS Omega
. 2024 Aug;
9(30):32418-32428.
PMID: 39100286
In this work, a one-pot multicomponent synthesis of the ibuprofen-loaded FeO nanoparticles-supported zeolitic imidazolate framework-8 (Ibu-ZIF-8/FeO NPs) nanohybrid was carried out. The ZIF-8/FeO NPs nanohybrid was used as a drug...
5.
Jyoti , Kumari S, Chakraborty S, Kanoo P, Kumar V, Chakraborty A
Dalton Trans
. 2024 May;
53(38):15815-15825.
PMID: 38771593
We present the use of an amine functionalized two-dimensional clay , aminoclay (AC), in the chemistry of a three-dimensional metal-organic framework (MOF) , MIL-101(Cr), to prepare MIL-101(Cr)/AC composites, which are...
6.
Schreiber S, Dressler L, Loffredo-Verde E, Asen T, Farber S, Wang W, et al.
Front Immunol
. 2024 May;
15:1340619.
PMID: 38711498
To design new CARs targeting hepatitis B virus (HBV), we isolated human monoclonal antibodies recognizing the HBV envelope proteins from single B cells of a patient with a resolved infection....
7.
Kumari S, Yadav A, Kumari A, Mahapatra S, Kumar D, Sharma J, et al.
Inorg Chem
. 2024 Apr;
63(16):7146-7160.
PMID: 38592926
The crystal structure of the metal-organic framework (MOF), {Mn(1,4-bdc)(DMF)} () (1,4-bdcH, 1,4-benzenedicarboxylic acid; DMF, ,-dimethylformamide), is known for a long time; however, its desolvated structure, {Mn(1,4-bdc)} (), is not yet...
8.
Loh W, Pang J, Chakraborty A, Ward N, Chan D, Hooper A, et al.
J Clin Lipidol
. 2023 Dec;
18(1):e33-e37.
PMID: 38040538
Elevated plasma lipoprotein(a) [Lp(a)] is a common, inherited condition independently causing cardiovascular disease. Recent expert recommendations suggest opportunistically testing for elevated Lp(a) during cascade testing for familial hypercholesterolaemia (FH). We...
9.
Yadav P, Kumari S, Yadav A, Bhardwaj P, Maruthi M, Chakraborty A, et al.
ACS Omega
. 2023 Aug;
8(31):28367-28375.
PMID: 37576664
Norfloxacin (NFX), an important antibacterial fluoroquinolone, is a class IV drug according to the biopharmaceutics classification system (BCS) and has low solubility and permeability issues. Such poor physicochemical properties of...
10.
Yadav P, Bhardwaj P, Maruthi M, Chakraborty A, Kanoo P
Dalton Trans
. 2023 Aug;
52(33):11725-11734.
PMID: 37555452
Drug delivery systems (DDSs) that are derived from biocompatible carriers are attractive platforms for sustained release of drugs. In particular, sustained and controlled release of poorly soluble BCS (Biopharmaceutics Classification...